Active	Status	Sponsor type	Region	Phase	Filter
4 Active 3 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
MIESBACH, Wolfgang
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)	Active, not recruiting	2	40	Europe, US, RoW	TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930	Takeda, Takeda Development Center Americas, Inc.	Thrombotic Thrombocytopenic Purpura (TTP)	03/25	03/25
PRESent-3, NCT05789537: A Study of SerpinPC in Participants with Hemophilia B (HemB) with Inhibitors	Active, not recruiting	2	3	Europe, US, RoW	SerpinPC, Activated Protein C (APC) inhibitor	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia B with Inhibitor, Hemophilia B	11/24	02/25
PRESent-2, NCT05789524: The Efficacy and Safety of SerpinPC in Participants with Severe Hemophilia a or Moderately Severe to Severe Hemophilia B	Active, not recruiting	2	60	Europe, Canada, US, RoW	SerpinPC, Activated Protein C (APC) inhibitor	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia a, Hemophilia B	11/24	02/25
PRESent-5, NCT05605678: Hemophilia Non-Interventional Study Prior to SerpinPC Intervention	Terminated	N/A	108	Europe, Canada, US, RoW	No Intervention	ApcinteX Ltd, Centessa Pharmaceuticals plc	Hemophilia a, Hemophilia B	11/24	11/24